
Cyclerion Therapeutics CYCN
$ 2.99
0.34%
Annual report 2024
added 11-12-2025
Cyclerion Therapeutics Total Liabilities 2011-2026 | CYCN
Annual Total Liabilities Cyclerion Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 55.9 M | 88.7 M | 17.8 M | 14 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 88.7 M | 14 M | 44.1 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 4.23 | 6.55 % | $ 10.2 B | ||
|
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | ||
|
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
707 M | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | ||
|
Akari Therapeutics, Plc
AKTX
|
19.6 M | $ 5.08 | -0.73 % | $ 342 B | ||
|
Aligos Therapeutics
ALGS
|
35 M | $ 6.98 | -8.88 % | $ 69 M | ||
|
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
4.18 B | $ 319.0 | -0.35 % | $ 41.8 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M | ||
|
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
840 M | $ 22.02 | 0.96 % | $ 1.03 B | ||
|
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | ||
|
BioNTech SE
BNTX
|
2.76 B | $ 103.6 | 1.45 % | $ 27.2 B | ||
|
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - | ||
|
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | ||
|
BioXcel Therapeutics
BTAI
|
140 M | $ 1.15 | 7.47 % | $ 14 M | ||
|
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
344 M | $ 1.35 | -0.74 % | $ 347 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
194 M | $ 4.33 | 1.64 % | $ 463 M | ||
|
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | ||
|
Arcutis Biotherapeutics
ARQT
|
243 M | $ 24.53 | 1.41 % | $ 3.12 B | ||
|
Burford Capital Limited
BUR
|
1.45 B | $ 4.78 | 2.36 % | $ 777 M | ||
|
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | ||
|
Cabaletta Bio
CABA
|
53 M | $ 3.23 | -8.24 % | $ 325 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 2.94 | -4.55 % | $ 4.84 M | ||
|
Autolus Therapeutics plc
AUTL
|
411 M | $ 1.64 | 1.55 % | $ 436 M | ||
|
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | ||
|
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | ||
|
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
425 M | - | - | $ 546 M | ||
|
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | ||
|
Cidara Therapeutics
CDTX
|
51.5 M | - | - | $ 1.41 B | ||
|
Celldex Therapeutics
CLDX
|
55.8 M | $ 34.74 | 2.6 % | $ 2.31 B | ||
|
CymaBay Therapeutics
CBAY
|
142 M | - | - | $ 3.45 B | ||
|
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M |